SLC7A11 and acute myeloid leukemia: Pardieu B et al. reported that higher expression of SLC7A11 is associated with poor outcome in AML patients, and genetic and chemical inhibition of SLC7A11 triggers ferroptosis and reduces viability [44], suggesting that cystine uptake inhibition might be a front-line therapy in AML.